Truist Securities Reiterates Buy on Bristol-Myers Squibb, Maintains $84 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregg Gilbert has reiterated a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY) and maintained an $84 price target.
September 15, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Bristol-Myers Squibb and maintained an $84 price target.
The reiteration of a 'Buy' rating by Truist Securities indicates their continued confidence in Bristol-Myers Squibb. The maintained price target of $84 suggests they believe the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100